Clinical trials: Circulating Platelet-monocyte Conjugates
Glioblastoma, Circulating Platelet-monocyte Conjugates
Glioblastoma Platelet Activation Study
Glioblastoma face an increased risk of venous or arterial thromboembolism. Furthermore, the most frequent immune cells in glioblastoma are tumor associated macrophages, which find theirself in an anti-inflammatory (M2) phenotype.
- Trial name
- GPAS (NCT02887417)
- Where
- Germany
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University Medicine Greifswald